NanoViricides Inc. (NNVC)

[KMBJN]

The animal results have identified at least 3 leads that can make it through IND - FluCide, HerpesCide, and HIVCide. The company simply doesn't have the capital or manufacturing capability to advance all of them. Given the constraints, they have wisely chosen to go after the least onerous candidate - topical HerpeCide, which they claim will require less stringent manufacturing conditions and smaller quantities/batches (200g/batch, which they claim to have now), with relatively quick and uncomplicated trials.

Mr. Market will be surprised when topical HerpesCide advances.

or perhaps NNVC will never get its act together enough to advance to IND.

We should find out soon enough (but not soon enough).